Authors' Reply

Reed, Grant W.; Guo, Jianping; Cannon, Christopher P.; Kumar, Amit; Aranki, Sary F.; Shekar, Prem; Agnihotri, Arvind K.; Maree, Andrew O.; McLean, Dalton; Rosenfield, Kenneth

doi:10.1002/clc.22413

Search citation statements

Order By: Relevance

Paper Sections

Select...

Omics Technologies and Precision Medicine1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2019

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Advances are already being made in this arena. For example, a POC platelet function device that predicts surgical bleeding risk and guides management in patients on clopidogrel has already shown promise . Similarly, a POC assay that tests for platelet function is being evaluated for guiding platelet transfusion in aspirin users with intracranial hemorrhage…”

Section: Omics Technologies and Precision Medicinementioning

confidence: 99%

The ‘Omics’ of Epigenetic Modulation by Valproic Acid Treatment in Traumatic Brain Injury—What We Know and What the Future Holds

Bhatti

Williams

Georgoff

et al. 2019

Proteomics Clinical Apps

View full text Add to dashboard Cite

Traumatic brain injury (TBI) is a heterogeneous injury that is a major cause of morbidity and mortality worldwide. Epigenetic modulation through the alteration of cellular acetylation by valproic acid (VPA) administration has shown promise as a novel pharmacological treatment for TBI. It improves clinical outcomes through multiple mechanisms, many of which are still poorly understood. In recent years, omics technologies have emerged as a promising strategy to detect molecular changes at the cellular level. This review highlights the use of these high throughput technologies in advancing the understanding of epigenetic modulation by VPA in TBI. It also describes the future role of omics techniques in developing a point of care test to guide patient selection for VPA administration.

show abstract

Section: Omics Technologies and Precision Medicinementioning

confidence: 99%